MedPath

Lung Transplantation for Pleuroparenchymal Fibroelastosis

Conditions
Fibroelastosis
Interventions
Procedure: Lung transplantation (single, lobar or bilateral lung transplantation)
Registration Number
NCT05044390
Lead Sponsor
Hospices Civils de Lyon
Brief Summary

This retrospective observational study will evaluate the outcomes of lung transplantation for a rare cause of interstitial lung disease called pleuroparenchymal fibroelastosis. Data will be collected from all transplantation center in France.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Lung transplantation (any type) for pleuroparenchymal fibroelastosis
  • Histologically confirmed pleuroparenchymal fibroelastosis on the recipient lungs
Read More
Exclusion Criteria
  • All other interstitial lung disease than pleuroparenchymal fibroelastosis
  • Pleuroparenchymal fibroelastosis who didn't underwent lung transplantation
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
lung transplantationLung transplantation (single, lobar or bilateral lung transplantation)Lung transplantation performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis.
Primary Outcome Measures
NameTimeMethod
Post-operative mortalityAny death up to 90 days after lung transplantation

Any death after lung transplantation during the first 30 days or during the hospitalization following the lung transplantation (in-hospital mortality)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

Bichat Claude Bernard Hospital, APHP

🇫🇷

Paris, France

Foch Hospital

🇫🇷

Suresnes, France

Marie Lannelongue Hospital

🇫🇷

Le Plessis-Robinson, France

Hopital Louis Pradel

🇫🇷

Lyon, France

© Copyright 2025. All Rights Reserved by MedPath